Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,460.00    44.00 (3.11%)
Bid:
1,453.00
Ask:
1,454.00
Spread: 1.00 (0.069%)
Market Cap: £3.10b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Dividend Declaration

4 Oct 2013 14:01

RNS Number : 7825P
Hikma Pharmaceuticals Plc
04 October 2013
 



 

Hikma Pharmaceuticals PLC

Interim & Special Dividend for 2013

LONDON, 4 October 2013 - Hikma Pharmaceuticals PLC ("the Company") advises that, as previously announced with the interim results, the Company is paying a total dividend of 10 cents per share, comprising the interim dividend of 7.0 cents and the special dividend of 3 cents, on 7 October 2013 to shareholders on the register on 6 September 2013.

Shareholders who have elected to receive their dividend in Pounds Sterling will receive 6.26 pence per Ordinary Share (exchange rate US$1.5974 to GBP£1).

Shareholders who have elected to receive their dividend in Jordanian Dinar will receive 7.08 qirsh (piastres) per Ordinary Share (exchange rate US$0.708 to JOD1).

- ENDS -

Enquiries:

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2670

Susan Ringdal

Investor Relations Director

 

+44 20 7399 2670

 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DIVMIBJTMBMMBMJ
Date   Source Headline
1st Oct 202511:45 amRNSBlock listing Interim Review
23rd Sep 20251:52 pmRNSDirector/PDMR Shareholding
17th Sep 20259:16 amRNSDirector/PDMR Shareholding
22nd Aug 202512:02 pmRNSDirector/PDMR Shareholding
13th Aug 20251:51 pmRNSDirector/PDMR Shareholding
8th Aug 202512:59 pmRNSDirector/PDMR Shareholding
7th Aug 20257:00 amRNSHalf-year Report
9th Jul 20259:00 amRNSNotice of Results
7th Jul 20259:16 amRNSPublication of Offering Circular
9th Jun 20253:33 pmRNSDirector/PDMR Shareholding
5th Jun 20252:05 pmRNSDirector/PDMR Shareholding
3rd Jun 20251:02 pmRNSDirector/PDMR Shareholding
29th May 20257:00 amRNSFitch upgrades Hikma to ‘BBB’
20th May 20252:49 pmRNSDirector/PDMR Shareholding
15th May 202512:00 pmRNSMedium-term Group guidance ahead of US site visit
8th May 20254:35 pmRNSDirector/PDMR Shareholding
8th May 202510:48 amRNSS&P upgrades Hikma to ‘BBB’
8th May 20258:21 amRNSSettlement agreement for Xyrem® US lawsuits
30th Apr 20251:21 pmRNSDirector/PDMR Shareholding
24th Apr 20253:55 pmRNSResult of AGM
24th Apr 20257:00 amRNSTrading Statement
10th Apr 20252:36 pmRNSDirector/PDMR Shareholding
8th Apr 20251:47 pmRNSDirector/PDMR Shareholding
1st Apr 20259:30 amRNSBlock listing Interim Review
19th Mar 202510:10 amRNSAnnual Financial Report and Notice of AGM
4th Mar 202511:16 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNSFinal Results
10th Feb 20258:09 amRNSNotice of Results
23rd Dec 20249:46 amRNSDirector/PDMR Shareholding
7th Nov 20243:30 pmRNSOutcome of Audit Tender Process
7th Nov 20247:00 amRNSTrading Statement
24th Oct 20247:00 amRNS2024 Annual General Meeting Update Statement
1st Oct 20249:45 amRNSBlock listing Interim Review
24th Sep 202410:09 amRNSDirector/PDMR Shareholding
10th Sep 20247:00 amRNSHikma completes Xellia acquisition
13th Aug 20249:39 amRNSDirector/PDMR Shareholding
8th Aug 20247:00 amRNSHalf-year Report
29th Jul 20244:08 pmRNSDirector Declaration
15th Jul 20247:00 amRNSNotice of Results
1st Jul 20242:47 pmRNSTotal Voting Rights
27th Jun 20241:47 pmRNSDirector Declaration
17th Jun 20247:00 amRNSHikma acquires Xellia’s assets
5th Jun 20242:53 pmRNSDirector/PDMR Shareholding
9th May 20249:49 amRNSDirector/PDMR Shareholding
25th Apr 20242:28 pmRNSResult of AGM
25th Apr 20247:00 amRNSTrading Statement
17th Apr 202410:42 amRNSDirector/PDMR Shareholding
15th Apr 20244:43 pmRNSHikma appoints new President of Generics business
11th Apr 202410:58 amRNSDirector/PDMR Shareholding
2nd Apr 20249:50 amRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.